Prelude Therapeutics, Inc. (PRLD)

NASDAQ: PRLD · IEX Real-Time Price · USD
4.47
-0.07 (-1.54%)
May 27, 2022 11:47 AM EDT - Market open
Market Cap207.56M
Revenue (ttm)n/a
Net Income (ttm)-119.86M
Shares Out46.43M
EPS (ttm)-2.58
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume27,999
Open4.52
Previous Close4.54
Day's Range4.34 - 4.53
52-Week Range3.87 - 43.55
Betan/a
AnalystsBuy
Price Target25.76 (+476.3%)
Earnings DateMay 10, 2022

About PRLD

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high k...

IndustryBiotechnology
IPO DateSep 25, 2020
Employees118
Stock ExchangeNASDAQ
Ticker SymbolPRLD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for PRLD stock is "Buy." The 12-month stock price forecast is 25.76, which is an increase of 476.29% from the latest price.

Price Target
$25.76
(476.29% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 in 2H2022

2 weeks ago - GlobeNewsWire

Prelude Therapeutics Reports Full Year 2021 Financial Results

Significant progress achieved in 2021: Pipeline now includes six internally discovered small molecule compounds targeting clinically validated pathways in cancers with underserved patients

2 months ago - GlobeNewsWire

Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference

WILMINGTON, Del., March 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer,...

2 months ago - GlobeNewsWire

Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022...

Announces strategic prioritization within lead programs targeting PRMT5 and MCL1

2 months ago - GlobeNewsWire

Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

WILMINGTON, Del., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (NASDAQ: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, ...

3 months ago - GlobeNewsWire

Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

WILMINGTON, Del., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, ...

4 months ago - GlobeNewsWire

The 10 Most Shorted Stocks Right Now for Friday, Dec. 17

Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we're diving into some top candidates! The post The 10 Most Shorted Stocks Right Now for Friday, Dec. 1...

5 months ago - InvestorPlace

Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference

WILMINGTON, Del., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, ...

6 months ago - GlobeNewsWire

Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update

PRT543 and PRT811 Demonstrate Favorable Safety Profile, Tolerability and Evidence of Preliminary Clinical Activity in Phase 1 Dose Escalation in Unselected Patients

6 months ago - GlobeNewsWire

Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor

Phase 1 Clinical Trial in Patients with Selected Solid Tumors Anticipated to Begin by Year-End Phase 1 Clinical Trial in Patients with Selected Solid Tumors Anticipated to Begin by Year-End

6 months ago - GlobeNewsWire

Why Did Prelude Therapeutics Stock Tumble To 52-Week Low Today?

Prelude Therapeutics Inc (NASDAQ: PRLD) has announced data from the dose-escalation portions of Phase 1 trials of PRT543 and PRT811.  The data will be featured at the AACR-NCI-EORTC Virtual Internationa...

7 months ago - Benzinga

Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual ...

– Lead oral PRMT5 inhibitors PRT543 and PRT811 demonstrate favorable safety profile, evidence of preliminary clinical activity including durable responses and high levels of target inhibition of PRMT5 i...

7 months ago - GlobeNewsWire

Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update

- Data from Dose Escalation Portion of Phase 1 Trials of Lead Oral PRMT5 Inhibitors  PRT543 and PRT811 to be Presented in 4Q21 –

9 months ago - GlobeNewsWire

Why BofA Is Turning Bullish On Prelude Therapeutics

Prelude Therapeutics Inc's (NASDAQ:PRLD) share price represents “a particularly attractive buying opportunity,” and the stock has catalysts in the back half of the year, according to BofA Securities. Th...

9 months ago - Benzinga

Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update

- Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 -

1 year ago - GlobeNewsWire

Prelude Therapeutics (PRLD) Enters Oversold Territory

Prelude Therapeutics (PRLD) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

1 year ago - Zacks Investment Research

Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences

WILMINGTON, Del., March 03, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that m...

1 year ago - GlobeNewsWire

Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purcha...

WILMINGTON, Del., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closin...

1 year ago - GlobeNewsWire

Prelude Therapeutics Announces Pricing of Upsized Public Offering

WILMINGTON, Del., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Wilmington, DE – January 7, 2021 – Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology ...

1 year ago - GlobeNewsWire

Prelude Therapeutics Announces Launch of Proposed Public Offering

WILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that it ha...

1 year ago - GlobeNewsWire

Prelude Therapeutics Announces Third Quarter 2020 Financial Results

- Completed I nitial P ublic O ffering of C ommon S tock, R aising G ross P roceeds of ~$ 181.9M -

1 year ago - GlobeNewsWire

Prelude Therapeutics Announces Dosing of First Patient in Phase 1 Trial of MCL1 Inhibitor PRT1419 for the Treatment o...

WILMINGTON, Del., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the first patient has been dosed ...

1 year ago - GlobeNewsWire

Prelude Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Pu...

WILMINGTON, Del., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its initial public of...

1 year ago - GlobeNewsWire

Prelude Therapeutics Announces Pricing of Initial Public Offering

WILMINGTON, Del., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its initial public of...

1 year ago - GlobeNewsWire